UCB, a Belgium-based global biopharmaceutical company, announced on Wednesday that it has introduced its Make HStory, an educational campaign that offers tools and resources for those living with hidradenitis suppurativa (HS) and their dermatologists.
HS is a chronic, complex, and debilitating inflammatory skin disease that impacts approximately 1% of the population in most studied countries, and large unmet needs remain. Make HStory intends to help increase understanding of the disease and to empower patients to have conversations with their dermatologist about management options.
The new campaign has been developed in collaboration with individuals living with HS and their dermatologists. It features stories of those living with HS, informational videos, and interactive tools and resources for those seeking management options, daily care, and information about HS. It was developed as a partner to the previously launched Make HStory medical education campaign, and offers educational information, downloadable resources, a strong online and streaming service video presence, and social media, including Instagram and Facebook.
Quoin Pharmaceuticals to study QRX003 for Peeling Skin Syndrome
Dragonfly Therapeutics names new chief financial officer
Formosa Pharmaceuticals secures exclusive Canadian licensing deal with Apotex
Bio-Techne invests in Spear Bio to boost ultra-sensitive immunoassay development
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
SFA Therapeutics names new chief operating officer
argenx and Zai Lab win China approval for efgartigimod SC
Scinai Immunotherapeutics reports positive results in psoriasis study
Spine BioPharma, signs agreement with Ensol BioSciences
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
Delta-Fly Pharma initiates Phase III trial for lung cancer drug DFP-14323
Q32 Bio added to Russell 3000 Index
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)